A phase I/II randomized study evaluated the safety and efficacy of sotorasib (Code Break 100: NCT03600883) in 126 patients with advanced stage KRAS G12C mutated NSCLC who were pre-treated with platinum-based therapy and inhibitors of programmed death 1 (PD-1). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.